Adenovirus vaccine vectors
AssigneeInstitut Gustave Roussy
InventorsKarim Benihoud, Anastasia Lanzi, Michel Perricaudet
Life of this patent
Estimating the term…
Abstract
The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity.
Claims10
A method of generating a humoral immune response against one or more target B-cell epitope(s) in a subject having a pre-existing humoral immunity against an adenovirus of a given serotype resulting from a previous exposure to a wild-type or recombinant adenovirus, comprising:
- administering to the subject a recombinant replication-defective adenovirus of the same serotype,
- wherein the subject has pre-existing humoral immunity to the same adenovirus serotype of said replication-defective adenovirus;
- said replication defective adenovirus has a heterologous polypeptide of up to 50 amino acids containing one or more target B-cell epitope(s) from a foreign antigen of interest inserted into the HI loop of the knob of a fiber protein of the replication-defective adenovirus, and an IgG humoral immune response against the target B-cell epitope(s) in the subject is enhanced by a pre-existing humoral immunity against said adenovirus serotype.
A method of generating a humoral immune response against one or more target B-cell epitope(s) in a subject comprising:
- (a) administering to the subject a recombinant replication-defective adenovirus having a heterologous polypeptide of up to 50 amino acids containing one or more target B-cell epitope(s) from a foreign antigen of interest inserted into the HI loop of the knob of a fiber protein of the recombinant replication deficient adenovirus, and
- (b) re-administering the recombinant replication-defective adenovirus at least once to the subject,
- wherein IgG humoral immune response against the target B-cell epitope(s) is enhanced by humoral immunity generated against the recombinant replication-defective adenovirus.
Dependencies are inferred from the claim text.